Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Core Insights - Entrada Therapeutics is advancing its clinical programs for Duchenne muscular dystrophy (DMD) and expects significant data releases in 2026, including results from the ELEVATE-44-201 and ELEVATE-45-201 studies [2][6] - The company reported a cash position of $327 million as of September 30, 2025, which is expected to fund operations into Q3 2027 [1][7] - Collaboration revenue decreased significantly to $1.6 million in Q3 2025 from $19.6 million in Q3 2024, primarily due to the completion of research activities related to VX-670 [8] Financial Performance - Cash, cash equivalents, and marketable securities were $326.8 million as of September 30, 2025, down from $420.0 million as of December 31, 2024, due to operational funding [7] - Research and development (R&D) expenses increased to $38.4 million in Q3 2025 from $31.3 million in Q3 2024, driven by costs associated with DMD programs and higher personnel expenses [9] - General and administrative (G&A) expenses rose slightly to $10.3 million in Q3 2025 from $10.0 million in Q3 2024, mainly due to increased personnel costs [10] Clinical Development Pipeline - Entrada is advancing multiple clinical programs for DMD, with three clinical-stage programs expected by year-end 2025 [3] - The company has completed enrollment for Cohort 1 of the ELEVATE-44-201 study and is on track to report data in Q2 2026 [6] - The first patient has been dosed in the ELEVATE-45-201 study, with data expected in mid-2026 [5][6] Preclinical Pipeline Expansion - Positive preclinical data has been generated for ocular and metabolic disease programs, with two ocular programs advancing to lead optimization [4] Regulatory and Future Plans - The company has filed for regulatory authorization in the U.K. to initiate the ELEVATE-50-201 study and plans to submit applications in the EU in the second half of 2026 [5][6]